Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06407102
Recruiting Not applicable

Collection of Primary Human

NCT06407102 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Tours
Phase
Not applicable
Started
2024-12-06
Last updated
2026-06-16

Condition(s) studied

Nasal Disease

Investigational drug(s) / intervention(s)

Collection of nasal cells during programme surgery

Collection of nasal cells during programme surgery: During programmed surgery (meatotomy, septoplasty or turbinoplasty for example, or other programmed surgeries), the surgeon will take an atraumatic sample from the nasal cavity using a dedicated device (brush) from the healthy nasal mucosa.

Study summary

Treatment and prevention of respiratory infections are of great interest in many medical areas. Create a physical device covered by primary human nasal cells could be very usefull in order to analyse delivery and efficiency of drugs. In this context the aim of this project is to create a collection of primary cells from the human nasal epithelium.

This collection will be realised during programmed surgery, thanks to a specific device dedicated to collect nasal cells. Then the cells will be sent to the lab in order to grow at the air-liquid interface, which is an excellent 'ex vivo' model for their study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Adult patients (age \> 18 years) whose native language is French, or who understands French. * Affiliation with a French social security system (CMU accepted). * Informed consent, written and signed by the participant. * Planned rhinological surgery (meatotomy, septoplasty or turbinoplasty for example, but other surgeries as well) Exclusion Criteria: * Patients under court protection, guardianship or curatorship. * Pregnant or breast-feeding women (positive pregnancy test for women of childbearing age). * Patients presenting a major alteration of the mucosa or a malignant rhinosinus pathology.

Primary outcome measure(s)

  • Percentage of viability of nasal epithelial cells from the operating room to laboratory — 6 hours
    Collect nasal epithelial cells that can be grown in vitro in an air-liquid interface

Trial sites (1)

FacilityCityRegionStatus
AUSSEDAT Tours France Recruiting

More University Hospital, Tours trials in France

Colorectal Cancer Screnning Colonoscopy Under Hypnosis Recruiting
Development, Standardisation and Standardisation Project for a New Memory Assessment Recruiting
Methoxyflurane Versus Usual Care for Non-Traumatic Pain in Emergency Departments Starting soon
Communication Enhancement Among Ventilated Patients in Intensive Care Recruiting
Impact on Delirium of the Use of DEXmedetomidine as First-line Sedation in PEDIAtric Intensive Care Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06407102 on ClinicalTrials.gov ↗ ← All trials in France